At one point after hours, Novavax (NASDAQ:NVAX) was down ~30% after STAT News reported that eight participants in a Phase 1 clinical trial evaluating COVID-19 vaccine candidate NVX-CoV2373 had to be hospitalized, a point later found to be erroneous. NVAX apparently contacted STAT to say that no subjects required hospitalization.
The stock is now down only 3% on turnover of 4.7M shares according to Nasdaq.
David S. Brown Enterprises has bolstered its Retail Leasing team with the recent hiring of Michael Gosnell
Kennedy Krieger Institute has announced the appointment of Dr. John Campo as Vice President of Psychiatric Services
Pessin Katz Law is pleased to announce that Attorney Adam E. Konstas has been elected to Member
Knollwood, the premier life plan community of choice for those 62 and better in NW Washington, D.C., known for
Editor in Chief, Warfield Digital
Connect
Independent Consultant
Connect
President of Lawrence Howard & Associates
Connect
Partner at Womble Carlyle, LLP
Connect
Owner at Develop DC
Connect
Stinson Marketing Group
Connect
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
